ALB 109564(a) is a novel analog from an established and marketed class of tubulin inhibitors, which is designed to kill cancer cells by preventing cell mitosis. In preclinical testing, the compound has a broad-spectrum effect in animal models, with efficacy superior to vinorelbine. Significant tumor growth delay was seen against human colon, lung and prostate solid tumors – as xenografts in mice – and against leukemia in mice.
This research program highlights AMRI's unique biocatalysis technology platform, natural products expertise, and high potency chemical development capabilities. AMRI has several issued patents and pending applications to protect the intellectual property associated with this compound, and is looking for a licensee to commercialize this technology.
Tubulin inhibitors have been used in the fight against cancer for decades to effectively block the polymerization of tubulin and interfere with microtubule formation, particularly in rapidly dividing cancer cells. In the absence of a proper mitotic spindle, duplicated chromosomes cannot align along the division plate. The cell senses that something is “wrong” and triggers cell death.
For more information, download the following posters pertaining to our tubulin program: